Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma

Kouloulias, VE; Nikita, KS; Kouvaris, JR; Golematis, BC; Uzunoglu, NK; Mystakidou, K; Vlahos, LJ

dc.contributor.author	Kouloulias, VE	en
dc.contributor.author	Nikita, KS	en
dc.contributor.author	Kouvaris, JR	en
dc.contributor.author	Golematis, BC	en
dc.contributor.author	Uzunoglu, NK	en
dc.contributor.author	Mystakidou, K	en
dc.contributor.author	Vlahos, LJ	en
dc.date.accessioned	2014-03-01T01:17:59Z
dc.date.available	2014-03-01T01:17:59Z
dc.date.issued	2002	en
dc.identifier.issn	0961-5423	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/14747
dc.subject	Chemotherapy	en
dc.subject	Intraoperative hyperthermia	en
dc.subject	Palliation	en
dc.subject	Pancreatic cancer	en
dc.subject	Quality of life	en
dc.subject	Radiotherapy	en
dc.subject.classification	Oncology	en
dc.subject.classification	Health Care Sciences & Services	en
dc.subject.classification	Rehabilitation	en
dc.subject.other	antineoplastic agent	en
dc.subject.other	cisplatin	en
dc.subject.other	doxorubicin	en
dc.subject.other	fluorouracil	en
dc.subject.other	octreotide	en
dc.subject.other	adenocarcinoma	en
dc.subject.other	adult	en
dc.subject.other	aged	en
dc.subject.other	article	en
dc.subject.other	clinical trial	en
dc.subject.other	female	en
dc.subject.other	human	en
dc.subject.other	hyperthermic therapy	en
dc.subject.other	male	en
dc.subject.other	middle aged	en
dc.subject.other	multimodality cancer therapy	en
dc.subject.other	pancreas tumor	en
dc.subject.other	peroperative care	en
dc.subject.other	Adenocarcinoma	en
dc.subject.other	Adult	en
dc.subject.other	Aged	en
dc.subject.other	Aged, 80 and over	en
dc.subject.other	Antineoplastic Combined Chemotherapy Protocols	en
dc.subject.other	Cisplatin	en
dc.subject.other	Combined Modality Therapy	en
dc.subject.other	Doxorubicin	en
dc.subject.other	Female	en
dc.subject.other	Fluorouracil	en
dc.subject.other	Humans	en
dc.subject.other	Hyperthermia, Induced	en
dc.subject.other	Intraoperative Care	en
dc.subject.other	Male	en
dc.subject.other	Middle Aged	en
dc.subject.other	Octreotide	en
dc.subject.other	Pancreatic Neoplasms	en
dc.title	Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma	en
heal.type	journalArticle	en
heal.identifier.primary	10.1046/j.1365-2354.2002.00294.x	en
heal.identifier.secondary	http://dx.doi.org/10.1046/j.1365-2354.2002.00294.x	en
heal.language	English	en
heal.publicationDate	2002	en
heal.abstract	The aim of this study was to evaluate the tolerability and the possible clinical benefit of intraoperative hyperthermia combined with multischedule chemotherapy and bypass surgery for the palliative treatment of inoperable pancreatic cancer. Ten patients with unresectable adenocarcinoma of the pancreas received preoperative chemotherapy [5-fluorouracil (5-FU)], bypass surgery and postoperative chemotherapy (5-FU, doxorubicin and cisplatin) plus sandostatin and radiotherapy (45 Gy, 25 fractions, 5 days a week). A single session of intraoperative hyperthermia was performed, by using a waveguide-type applicator (433 MHz). The tumour region was heated to 43-45degreesC for up to 60 min, while 500 mg 5-FU was infused simultaneously through the gastroduodenal into the splenic artery. Postoperative recovery was uneventful for all patients. A brief instrument was developed for evaluating patients' quality of life. Chemotherapy-related toxicity included myelosuppression, vomiting, alopecia and increase in blood urea nitrogen (BUN), creatinine, SGOT and SGPT. Glucose and amylase determinations remained within normal limits throughout the whole treatment. There was a significant improvement before and 1 month after combined treatment in Eastern Cooperative Oncology Group (ECOG) status (1.8 +/- 0.4), Scott-Huskinsson pain scale (3.2 +/- 0.8) and quality of life score (30.5 +/- 6.7). No progressive disease was noticed and the median overall survival was 11 (SE = 2.4) months. There was also a significant (P = 0.002, Wilcoxon test) decrease in values of both serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9), from 7.6 +/- 1.3 ng/mL and 875.7 +/- 104.8 U/mL to 3.5 +/- 0.7 ng/mL and 65.3 +/- 14.1 U/mL respectively. The first clinical results suggest a potential advantage of using combined intraoperative hyperthermia, chemotherapy and postoperative radiotherapy in the palliative treatment of the adenocarcinoma of the pancreas. The whole procedure seems to be free of perioperative morbidity, while the chemotherapy toxicity was rather moderate. However, the preliminary nature limits the general applicability of our results.	en
heal.publisher	BLACKWELL PUBLISHING LTD	en
heal.journalName	European Journal of Cancer Care	en
dc.identifier.doi	10.1046/j.1365-2354.2002.00294.x	en
dc.identifier.isi	ISI:000176643800018	en
dc.identifier.volume	11	en
dc.identifier.issue	2	en
dc.identifier.spage	100	en
dc.identifier.epage	107	en